Natural HPV immunity and vaccination strategies

Peter L. Stern; Michael Brown; Simon N. Stacey; Henry C. Kitchener; Ian Hampson; El Said Abdel-Hady; Jim V. Moore

doi:10.1016/S1386-6532(00)00128-1

Natural HPV immunity and vaccination strategies

Peter L. Stern, Michael Brown, Simon N. Stacey, Henry C. Kitchener, Ian Hampson, El Said Abdel-Hady, Jim V. Moore

Research output: Contribution to journal › Article › peer-review

388 Downloads (Pure)

Abstract

Background: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. Conclusion: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia. (C) 2000 Elsevier Science B.V.

Original language	English
Pages (from-to)	57-66
Number of pages	9
Journal	Journal of Clinical Virology
Volume	19
Issue number	1-2
DOIs	https://doi.org/10.1016/S1386-6532(00)00128-1
Publication status	Published - 2000

Keywords

Human papillomavirus (HPV)
Prophylaxis and therapy
Vaccines
Vulval intraepithelial neoplasia

Access to Document

10.1016/S1386-6532(00)00128-1

POST-PEER-REVIEW-PUBLISHERS.PDFFinal published version, 95.8 KB

Cite this

@article{d7c25a8b51244c469a43ac91fb3f1ef0,

title = "Natural HPV immunity and vaccination strategies",

abstract = "Background: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. Conclusion: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia. (C) 2000 Elsevier Science B.V.",

keywords = "Human papillomavirus (HPV), Prophylaxis and therapy, Vaccines, Vulval intraepithelial neoplasia",

author = "Stern, {Peter L.} and Michael Brown and Stacey, {Simon N.} and Kitchener, {Henry C.} and Ian Hampson and Abdel-Hady, {El Said} and Moore, {Jim V.}",

year = "2000",

doi = "10.1016/S1386-6532(00)00128-1",

language = "English",

volume = "19",

pages = "57--66",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier BV",

number = "1-2",

}

TY - JOUR

T1 - Natural HPV immunity and vaccination strategies

AU - Stern, Peter L.

AU - Brown, Michael

AU - Stacey, Simon N.

AU - Kitchener, Henry C.

AU - Hampson, Ian

AU - Abdel-Hady, El Said

AU - Moore, Jim V.

PY - 2000

Y1 - 2000

N2 - Background: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. Conclusion: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia. (C) 2000 Elsevier Science B.V.

AB - Background: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. Objectives: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. Conclusion: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia. (C) 2000 Elsevier Science B.V.

KW - Human papillomavirus (HPV)

KW - Prophylaxis and therapy

KW - Vaccines

KW - Vulval intraepithelial neoplasia

U2 - 10.1016/S1386-6532(00)00128-1

DO - 10.1016/S1386-6532(00)00128-1

M3 - Article

SN - 1386-6532

VL - 19

SP - 57

EP - 66

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

IS - 1-2

ER -

Natural HPV immunity and vaccination strategies

Abstract

Keywords

Access to Document

Fingerprint

Cite this